|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
82,270,000 |
Market
Cap: |
219.66(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$3.16 - $32.51 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 8.1 |
Insider 6 Months : 8.1 |
Insider 3/6 Months : 16.7 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Revance Therapeutics is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. Co.'s segments are: Product, which refers to the business that includes the research, development and commercialization of its product candidates and the RHA® Collection of dermal fillers; and Service, which refers to the business that includes the development and commercialization of the OPUL Relational Commerce Platform and HintMD platform.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
30,000 |
30,000 |
30,000 |
30,000 |
Total Buy Value |
$209,400 |
$209,400 |
$209,400 |
$209,400 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
1 |
1 |
1 |
Total Shares Sold |
29,089 |
29,089 |
157,681 |
446,160 |
Total Sell Value |
$143,717 |
$143,717 |
$3,260,512 |
$12,719,522 |
Total People Sold |
4 |
4 |
5 |
5 |
Total Sell Transactions |
4 |
4 |
13 |
27 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Schilke Tobin |
CFO |
|
2020-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
15,750 |
55,308 |
|
- |
|
Foley Mark J |
CEO & President |
|
2020-09-30 |
4 |
D |
$25.14 |
$3,601,783 |
D/D |
(143,269) |
571,231 |
|
- |
|
Foley Mark J |
CEO & President |
|
2020-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
301,000 |
714,500 |
|
- |
|
Joshi Abhay |
COO, President, R&D |
|
2020-09-30 |
4 |
D |
$25.14 |
$185,583 |
D/D |
(7,382) |
111,950 |
|
- |
|
Joshi Abhay |
COO, President, R&D |
|
2020-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
119,332 |
|
- |
|
Rankin Aubrey |
President, Innovation & Tech |
|
2020-09-28 |
4 |
AS |
$26.18 |
$867,055 |
I/I |
(33,119) |
576,922 |
|
12% |
|
Foley Mark J |
CEO & President |
|
2020-07-23 |
4 |
A |
$0.00 |
$0 |
I/I |
50,913 |
70,913 |
|
- |
|
Foley Mark J |
CEO & President |
|
2020-07-23 |
4 |
A |
$0.00 |
$0 |
D/D |
264,439 |
835,670 |
|
- |
|
Rankin Aubrey |
President, Innovation & Tech |
|
2020-07-23 |
4/A |
A |
$0.00 |
$0 |
I/I |
610,041 |
610,041 |
|
- |
|
Rankin Aubrey |
President, Innovation & Tech |
|
2020-07-23 |
4/A |
A |
$0.00 |
$0 |
D/D |
57,251 |
67,871 |
|
- |
|
Rankin Aubrey |
President, Innovation & TechOf |
|
2020-07-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
261,453 |
|
2% |
|
Rankin Aubrey |
President, Innovation & TechOf |
|
2020-07-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,620 |
|
2% |
|
Rankin Aubrey |
President, Innovation & Tech |
|
2020-07-23 |
4 |
A |
$0.00 |
$0 |
D/D |
667,292 |
667,292 |
|
- |
|
Schilke Tobin |
CFO |
|
2020-06-30 |
4 |
A |
$13.80 |
$10,526 |
D/D |
763 |
39,558 |
|
- |
|
Sjuts Dustin S |
Chief Commercial Officer |
|
2020-06-30 |
4 |
A |
$13.80 |
$13,796 |
D/D |
1,000 |
34,064 |
|
- |
|
Vickers Philip J. |
Director |
|
2020-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
19,650 |
|
- |
|
Gangolli Julian S |
Director |
|
2020-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
16,500 |
|
- |
|
Byrnes Robert F |
Director |
|
2020-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
16,500 |
|
- |
|
Gardner Phyllis |
Director |
|
2020-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
16,500 |
|
- |
|
Russell Angus C. |
Director |
|
2020-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
16,500 |
|
- |
|
Nolet Chris |
Director |
|
2020-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
15,000 |
|
- |
|
Beraud Jill |
Director |
|
2020-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
15,000 |
|
- |
|
Sjuts Dustin S |
Chief Commercial Officer |
|
2020-04-15 |
4 |
D |
$14.80 |
$6,394 |
D/D |
(432) |
33,064 |
|
- |
|
Joshi Abhay |
COO, President of R&D |
|
2020-03-15 |
4 |
D |
$15.50 |
$20,987 |
D/D |
(1,354) |
101,832 |
|
- |
|
Moxie Dwight |
SVP, GC & Secretary |
|
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
|
- |
|
422 Records found
|
|
Page 7 of 17 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|